Abstract
Eosinophilic Cystitis (EoC) is a rare disorder of the bladder resulting in lower abdominal pain, hematuria and dysuria. Standard treatment of antihistamines, leukotriene antagonists, NSAID's, cyclosporine, hydroxyurea and intravesicular corticosteroids is not always effective. Benralizumab is a monoclonal antibody directed against the IL-5 receptor, reducing eosinophil production and survival. Unlike other antagonists of IL-5, it is very effective in tissue depletion of eosinophils. It has previously been shown to be effective in EoC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
